

Silvia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7105165/silvia-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

895
citations

15
h-index

29
g-index

47
ext. papers

1,059
ext. citations

3.8
avg, IF

3.38
L-index

#	Paper	IF	Citations
47	Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?. <i>European Journal of Clinical Pharmacology</i> , 2022 , 1	2.8	0
46	The Influence of Sex, Gender, and Age on COVID-19 Data in the Piedmont Region (Northwest Italy): The Virus Prefers Men. <i>Life</i> , 2022 , 12, 643	3	1
45	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022 , 15, 630	5.2	
44	Gender-specific side effects of chemotherapy in pancreatic cancer patients.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021 , 1-7	2.4	0
43	Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. <i>Life</i> , 2021 , 11,	3	2
42	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. <i>Pharmacological Research</i> , 2021 , 173, 105848	10.2	5
41	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020 , 12,	6.6	14
40	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020 , 45, 405-412	2.7	1
39	Correlated quantification using microbiological and electrochemical assays for roxithromycin determination in biological and pharmaceutical samples. <i>Talanta</i> , 2020 , 211, 120703	6.2	1
38	Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring. <i>Blood</i> , 2019 , 134, 3547-3547	2.2	
37	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 417-427	3.5	4
36	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
35	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 17-22	1.9	4
34	Clinical relevance of deferasirox trough levels in thalassaemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 213-216	3	3
33	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 197-203	3.8	23
32	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 199-206	1.9	1
31	CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. <i>PLoS ONE</i> , 2018 , 13, e0196931	3.7	5

30	Deferasirox pharmacokinetic evaluation in β -thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 525-528	4.8	4
29	Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns. <i>Molecular and Cellular Biochemistry</i> , 2017 , 434, 51-60	4.2	5
28	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017 , 18, 539-554	2.6	10
27	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 1083-1088	3	13
26	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1524-1530	4.8	6
25	Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2017 , 177, 361-367	6.5	19
24	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017 , 5,	4.8	12
23	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016 , 17, 561-72	2.6	13
22	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β -thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 84, 1510-1512	7.5	2
21	Deferasirox pharmacokinetic and toxicity correlation in β -thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 1417-1421	4.8	9
20	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolism. <i>Molecular and Cellular Endocrinology</i> , 2015 , 401, 105-10	4.4	18
19	A current perspective on treatment of adrenocortical carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 911-921	1.1	2
18	Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 410-2	3.2	9
17	Practical treatment using mitotane for adrenocortical carcinoma. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014 , 21, 159-65	4	25
16	Quantification of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia: Comparison Between HPLC/UV and LC/MS/MS. <i>International Journal of Peptide Research and Therapeutics</i> , 2013 , 19, 109-116	2.1	5
15	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 293-300	1.9	29
14	Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats. <i>Psychoneuroendocrinology</i> , 2012 , 37, 1234-47	5	4
13	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 59, 109-16	3.5	53

12	In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2012 , 74, 201-210		70
11	A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 893-894, 127-33	3.2	24
10	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2012 , 166, 451-8	6.5	104
9	Short QT syndrome in infancy. Therapeutic drug monitoring of hydroquinidine in a newborn infant. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 982-4	3.8	2
8	A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. <i>Journal of Chromatographic Science</i> , 2011 , 49, 753-7	1.4	29
7	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. <i>Endocrine-Related Cancer</i> , 2010 , 17, 445-53	5.7	106
6	Intense physical exercise increases systemic 11beta-hydroxysteroid dehydrogenase type 1 activity in healthy adult subjects. <i>European Journal of Applied Physiology</i> , 2010 , 108, 681-7	3.4	21
5	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1721-6	3.2	82
4	Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009 , 116, 29-36	5.1	24
3	Mitotane 2009 , 369-381		
2	The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2008 , 159, 569-76	6.5	15
1	Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. <i>Endocrine-Related Cancer</i> , 2008 , 15, 1043-53	5.7	106